Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Sai-Hong Ignatius Ou"'
Autor:
Geoffrey I. Shapiro, Liza C. Villaruz, Jeffrey W. Clark, Alexander Drilon, Gregory J. Riely, Danielle Murphy, Tiziana Usari, D. Ross Camidge, Miyako Satouchi, Paul K. Paik, Sherry Li, Mark M. Awad, Toyoaki Hida, Jared Weiss, Rebecca S. Heist, Hidetoshi Hayashi, Sherry C. Wang, Benjamin Solomon, Sai-Hong Ignatius Ou, Keith D. Wilner, Gregory A. Otterson
Publikováno v:
Nature medicine
MET exon 14 alterations are oncogenic drivers of non-small cell lung cancers (NSCLCs).1 These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition.2 Crizotinib is a multikinase inhibitor with potent act
Autor:
John V. Heymach, Michael E. Goldberg, Niamh Long, Darragh Halpenny, Neelesh Sharma, William J. Geese, Jennifer L. Sauter, David R. Spigel, Ignacio I. Wistuba, Gaurav Singal, Jose A. Bufill, Alexa B. Schrock, Andrew J. Plodkowski, Roxana Azimi, Jaime Rodriguez-Canales, Neda Kalhor, Lee A. Albacker, Pan Tong, Mari Mino-Kenudson, Joseph D. Szustakowski, Elizabeth Jimenez Aguilar, Pamela Villalobos, Lynette M. Sholl, Ryan J. Hartmaier, Edwin Roger Parra, Robin Edwards, Mizuki Nishino, Patrik Vitazka, Vincent A. Miller, Jing Wang, Yasir Elamin, Charles M. Rudin, Brett W. Carter, Jeremy J. Erasmus, Warren Denning, Ariella Sasson, David Fabrizio, Matthew D. Hellmann, Philip J. Stephens, Giulia Costanza Leonardi, Sujaya Srinivasan, Julia A. Elvin, Sally E. Trabucco, Jeffrey S. Ross, Alice T. Shaw, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Nir Peled, Stefan Kirov, Danielle Greenawalt, Taghreed Hirz, Pasi A. Jänne, Siraj M. Ali, Jedd D. Wolchok, Ferdinandos Skoulidis, Péter Szabó, Kwok-Kin Wong, Jianjun Zhang, Haifa Hamdi, Justin F. Gainor, Garrett M. Frampton, Sai-Hong Ignatius Ou, Mark M. Awad, Hira Rizvi, Fei Jiang, Han Chang, Achim A. Jungbluth, Ana Galan-Cobo
Publikováno v:
Cancer Discovery. 8:822-835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subg
Autor:
Balazs Halmos, James Suh, Jane Liu, Manuel Doria, Jeffrey S. Ross, Sai-Hong Ignatius Ou, K. Cynthia Hsieh, Ranee Mehra, Vincent A. Miller, James A. Knost, Paul A. S. Fishkin, Philip J. Stephens, Garrett M. Frampton, Steven C. Buck, Alexa B. Schrock, Nir Peled, Nagla Abdel Karim, Siraj M. Ali, Jose A. Bufill, Rong Chen, Eduardo Braun, Shuyu D. Li
Publikováno v:
Journal of Thoracic Oncology. 12:932-942
Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic strategies for PSC has been hampered because of limited and inconsistent molecular charact
Autor:
Philip J. Stephens, Vincent A. Miller, Sai-Hong Ignatius Ou, Jeffrey S. Ross, Siraj M. Ali, Justin M. Allen, Rachel L. Erlich, Alexa B. Schrock, Davood Vafai
Publikováno v:
Clinical Lung Cancer. 18:e219-e222
Autor:
Barbara J. Gitlitz, Melissa Lynne Johnson, Gary Steinecker, James Suh, Eduard V. Bocharov, Jon Chung, Carolina Kawamura Haddad, Paulo Vidal Campregher, Siraj M. Ali, Samuel J. Klempner, Vincent A. Miller, Vamsidhar Velcheti, Jeffrey S. Ross, Philip J. Stephens, Alexa B. Schrock, Sai-Hong Ignatius Ou
Publikováno v:
Journal of Thoracic Oncology. 12(3):446-457
Introduction Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2 V659E , HER2 G660D ) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown. Methods We prospect
Autor:
Athanassios Argiris, Steffan N. Ho, Keith D. Eaton, Weiwei Tan, Martin Gutierrez, Francisco Robert, Sai-Hong Ignatius Ou, Ramaswamy Govindan, Gregory A. Otterson, Alain C. Mita, Nicoletta Brega, Tiziana Usari
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 12, iss 1
J Thorac Oncol
J Thorac Oncol
Introduction This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC. Methods Patients with NSCLC and an Eastern Coope
Autor:
James Suh, Balazs Halmos, Sai-Hong Ignatius Ou, Gregory P. Kalemkerian, Kurt Leuenberger, Vincent A. Miller, Zachary R. Chalmers, Jeffrey S. Ross, Garrett M. Frampton, Philip J. Stephens, Jonathan H. Goldman, Margaret Rosenzweig, Rachel L. Erlich, Siraj M. Ali, Alexa B. Schrock, Nir Peled, Patrick M. Forde
Publikováno v:
Journal of Thoracic Oncology. 11(9):1493-1502
Background The hepatocyte growth factor receptor gene ( MET ) exon 14 skipping ( METex14 ) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibi
Autor:
Xue Wu, Xingyang Xue, Misako Nagasaka, Huaxin Ding, Xingsheng Hu, Hui Xia, Qiuxiang Ou, Yang W. Shao, Sai-Hong Ignatius Ou
Publikováno v:
Clinical lung cancer. 21(3)
Background Neurotrophin receptor kinase (NTRK) gene fusions (NTRK+) are rare but actionable oncogenic drivers present in a wide variety of solid tumors. However, the clinicopathologic characteristics of NTRK1 fusion–positive non–small-cell lung c
Publikováno v:
JCO Precision Oncology
Autor:
Justin F. Gainor, James W. Rocco, Sai-Hong Ignatius Ou, Aina Zurita Martinez, Mari Mino-Kenudson, Marguerite Rooney, Alice T. Shaw, Mroz E, Catherine J. Wu, Daniel Rosebrock, Jaegil Kim, J. A. Engelman, Dimitri Livitz, Jiachen Lin, Ignaty Leshchiner, Oliver Spiro, Liudmila Elagina, Ivana Bozic, Chip Stewart, Gad Getz
Driver mutations alter cells from normal to cancer through several evolutionary epochs: premalignancy, early malignancy, subclonal diversification, metastasis and resistance to therapy. Later stages of disease can be explored through analyzing multip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f8acc1be28e99b1eb24bd785ac08e68